Trial Profile
A study evaluating influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2018
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary) ; Omeprazole
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors UCB
- 08 Feb 2018 New trial record